Immunovant, Inc. (IMVT)
IMVTNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$35.36
+4.83 (+15.83%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $7.26bn
- P/E
- –
- EPS, last 4 quarters
- $-2.82
- Dividend yield
- –
- Day range
- –
- 52-week range
- $21.43 to $45.42
- Average volume
- 1.42m
- Previous close
- $30.53
Analysts
10 coveringBuy8 buy, 2 hold, 0 sell
Targets a year out average $48.22, +36.4% from here
Earnings
next estimate $-0.7300Next report
Sep 2025
-1.4%
Dec 2025
+15.3%
Mar 2026
-21.7%
Jun 2026
-13.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$131.76m | -$114.36m | -$159.55m | -$160.32m |
| Net income | -$126.50m | -$110.64m | -$147.86m | -$153.22m |
News
8 latest- Immunovant (IMVT) Q2 2027 Earnings Call TranscriptThe Motley Fool · 17 minutes ago
- Stock Indexes Surge as Buyers Return to Chipmakers and AI StocksBarchart · 40 minutes ago
- Stock Indexes Sharply Higher as Tech Stocks Rally and Crude Oil FallsBarchart · 2 hours ago
- Strength in Tech and Weakness in Crude Oil Boost StocksBarchart · 2 hours ago
- Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain RTTNews · 6 hours ago
- Immunovant, Inc. Reports IMVT-1402 Clinical Updates and Financial Results for the Quarter Ended September 30, 2026Fintel · 9 hours ago
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study RTTNews · Sep 25, 2026
- IMVT Ends Cutaneous Lupus Erythematosus Program, Stock DownZacks · Sep 24, 2026
The company
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases and is a majority-owned subsidiary of Roivant. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- immunovant.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.